Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer
Perez, E.A.; Gandara, D.R.
Seminars in Oncology 21(3 Suppl 4: 2-5
1994
ISSN/ISBN: 0093-7754 PMID: 8209273 Document Number: 434251
Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.
Document emailed within 1 workday
Related Documents
Unsal, M.; Erturk, D. 2003: Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer Saudi Medical Journal 24(6): 628-631Shirinian, M.; Lee, J.S.; Dhingra, H.H.; Greenberg, J.; Hong, W.K. 1992: Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report Seminars in Oncology 19(6 Suppl. 12): 58-63
Manegold, C. 1998: Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer Seminars in Oncology 25(4 Suppl 9: 18-22
Lee, H-W.; Choi, J-H.; Lim, H-Y.; Park, J.S.; Kim, H.C.; Kang, S.; Oh, Y.T.; Chun, M.; Sheen, S.S.; Oh, Y.J.; Park, K.J.; Hwang, S.C. 2006: The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis Neoplasma 53(1): 30-36
Kosmidis, P.A.; Samantas, E.; Fountzilas, G.; Pavlidis, N.; Apostolopoulou, F.; Skarlos, D. 1994: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase IIi study. Hellenic Cooperative Oncology Group for Lung Cancer Trials Seminars in Oncology 21(3 Suppl 6: 23-30
Lorigan, P.; Lee, S.M.; Betticher, D.; Woodhead, M.; Weir, D.; Hanley, S.; Hardy, C.; Thatcher, N. 1995: Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer Seminars in Oncology 22(3 Suppl 7: 32-41
Thongprasert, S. 2000: Phase Ii study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer Journal of the Medical Association of Thailand 83(5): 549-553
Soh, L.T.; Tan, E.H.; Ang, P.T. 1998: Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer Singapore Medical Journal 39(8): 357-358
Palackdharry, C.S.; Krigel, R.L. 1994: Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer Seminars in Oncology 21(3 Suppl 4: 6-11
Joss, R.A.; Alberto, P.; Obrecht, J.P.; Barrelet, L.; Holdener, E.E.; Siegenthaler, P.; Goldhirsch, A.; Mermillod, B.; Cavalli, F. 1984: Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide Cancer Treatment Reports 68(9): 1079-1084
Chen, Y.M.; Perng, R.P.; Yang, K.Y.; Wu, H.W.; Lin, W.C.; Liu, J.M.; Tsai, C.M.; Whang-Peng, J. 2000: Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer Zhonghua Yi Xue Za Zhi 63(8): 605-611
Chewaskulyong, B.; Thongprasert, S. 1998: Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer Journal of the Medical Association of Thailand 81(1): 37-41
Splinter, T.; Kok, T.; Kho, S.; Lameris, H.; ten Kate, F.; Dalesio, O.; Dolman, B.; Palmen, F.; Bouvy, J.; Burghouts, J. 1986: A multicenter phase Ii trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer Seminars in Oncology 13(3 Suppl 3: 97-103
Fujita, A.; Igami, Y.; Takabatake, H.; Tagaki, S.; Yamamoto, R.; Sekine, K. 1999: Period of time patients with advanced non-small cell lung cancer could remain at home during CIC--therapy (cisplatin + ifosfamide + CPT-11) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(6): 805-811
Baldini, E.; Silvano, G.; Tibaldi, C.; Campoccia, S.; Cionini, L.; Conte, P. 2000: Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase Ii study Seminars in Oncology 27(1 Suppl 1: 28-32
Bilgi, O.; Karagoz, B.; Alacacioglu, A.; Ozgun, A.; Tuncel, T.; Gokhan-Kandemir, E. 2010: Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 15(2): 395
Fujita, A.; Takabatake, H.; Tagaki, S.; Sekine, K. 1998: Pilot study of cisplatin, ifosfamide and irinotecan (CPT-11) with granulocyte colony-stimulating factor support (CIC-regimen) in relapsed small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(5): 761-764
Palmer, A.J.; Brandt, A. 1996: The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages IIi B and IV non-small cell lung cancer: an Italian perspective Monaldi Archives for Chest Disease 51(4): 279-288
Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Thongprasert, S.; Chewaskulyong, B. 2004: Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer Journal of the Medical Association of Thailand 87(10): 1162-1167